key: cord-0914330-0nbm99uc
authors: Dodig, Dubravka; Fritzler, Marvin J.; Naraghi, Ali; Tarnopolsky, Mark A.; Lu, Jian‐Qiang
title: Immune‐mediated necrotizing myopathy after BNT162b2 vaccination in a patient with antibodies against receptor‐binding domain of SARS‐CoV‐2 and signal recognition particle
date: 2022-01-19
journal: Muscle Nerve
DOI: 10.1002/mus.27483
sha: f4fa90efb439073614aa8cd00be86ed2c508df5c
doc_id: 914330
cord_uid: 0nbm99uc

nan

drome. 1 We report a case of immune-mediated necrotizing myopathy (IMNM) after BNT162b2 vaccination associated with antibodies against the receptor-binding domain (RBD) of the severe acute respiratory system coronavirus-2 (SARS-CoV-2) spike protein and autoantibodies to signal recognition particle (SRP).

A previously healthy 55-year-old woman received her first dose of BNT162b2 vaccine ( Figure 1 ). The next day she developed myalgia, chills, fatigue, and vague generalized weakness. On day 21, after she received a second dose of BNT162b2 vaccine, the symptoms worsened to progressive weakness, and on day 49 she presented to an emergency department unable to walk. Her serum creatine kinase (CK) level was 7967 IU/L (normal, <190 IU/L). She was treated for rhabdomyolysis with intravenous fluids and discharged home, but she returned on day 56 with persistent symptoms.

Neurological examination revealed normal cranial nerve functions.

There was symmetrical weakness of the proximal upper and lower extremity muscles, graded 2 to 3/5 on the Medical Research Council The antinuclear antibody test by indirect immunofluorescence antibody on day 47 was positive (≥1:640; normal, <1:80) with a cytoplasmic (reticular) pattern, suggestive of antibodies to cytoplasmic targets. 2 Anti-SRP autoantibodies were identified ( Figure 1 ). SARS-CoV-2 tests by reverse transcription-polymerase chain reaction assay of nasopharyngeal swabs were negative on days 58, 67, and 208. On day 98, serum was tested for SARS-CoV-2 antibodies using a Food and Drug Administration early-use-authorized xMAP assay detecting immunoglobulin G (IgG) antibodies to nucleocapsid, S1, and RBD of S1 (anti-S1-RBD; Luminex Corp, Austin, Texas), measured as median fluorescence intensity (MFI). The seronegative reference range for all three analytes was 0 to 700 MFI. The patient had high-titer anti-S1-RBD IgG antibody (MFI = 2604) but normal-range antibodies to nucleocapsid (MFI = 109) and S1 (MFI = 294), consistent with a response to the mRNA vaccination.

On day 64, a muscle biopsy of the left vastus lateralis was examined. 3 The muscle showed myopathic changes, including necrotic myofibers; regenerating myofibers, scattered to focally aggregated CD68 + macrophages with rare CD4 + or CD8 + T cells;

and focal major histocompatibility complex-1 expression F I G U R E 1 Disease course with associated creatine kinase changes and treatment. The first and second doses of vaccine were injected into the right deltoid muscle. Fatigue and weakness persisted for 3 weeks after the first vaccine dose. The patient had difficulty getting up from a chair and climbing stairs. Anti-signal recognition particle autoantibodies were identified by the immunoblot method on UROIMMUN's EUROBlotMaster. Despite treatment with intravenous immunoglobulin of 1 to 2 g/kg every 4 weeks, high-dose prednisone, and methotrexate, follow-up (6-9 months) assessments demonstrated residual weakness graded 3 to 4/5 on the Medical Research Council scale bilaterally in the proximal muscles of the upper and lower extremities with persistently elevated creatine kinase levels F I G U R E 2 Legend on next page. 

We confirm we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Dubravka Dodig MD 1

Surveillance for adverse events after COVID-19 mRNA vaccination

How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from the ICAP initiative

Increased intramitochondrial lipofuscin aggregates with spherical dense body formation in mitochondrial myopathy

Mitophagy in three cases of immune-mediatednecrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: ultrastructural and immunohistochemical studies

Immune-mediated necrotizing myopathy: clinical features and pathogenesis

Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy

BNT162b2 mRNA SARS-CoV-2 vaccine elicits high avidity and neutralizing antibodies in healthcare workers

Axial short-tau inversion recovery images demonstrate increased signal intensity in the bilateral iliopsoas (A) (arrows), gluteus minimus (A) (arrowheads), adductors and obturator externus (B) (arrows), and semimembranosus (C) (arrows) muscles, and mild intermuscular edema between the rectus femoris and vastus lateralis (B) (arrowheads), with milder involvement of the left vastus medialis, intermedius, and lateralis, as well as right adductor magnus and biceps femoris (C) (asterisk). The vastus lateralis muscle biopsy shows necrotic myofibers in (D) (hematoxylin-eosin stain) and (E) (Gomori trichrome stain) (arrows), regenerating myofibers in (D-F) (arrowheads), and capillary endothelial cells containing positive granules in (F) (succinate dehydrogenase stain) (arrows), scattered to aggregated CD68 + macrophages in (G) (arrows), rare CD8 + T cells in (H), and major histocompatibility complex-1 expression extensively in the necrotic myofibers and focally in some non